Histamine release after injection of benzodiazepines and of etomidate. A problem associated with the solvent propylene glycol (= Libération d'histamine après injection de benzodiazépines et d'étomidate. Rôle du solvant propylène-glycol) by Doenicke, A. et al.
© Masson, Paris. ANAPHYLACTOID R ISK  
Ann Fr Anesth Reanim, 12: 166-168, 1993 IN  ANAESTHESIA  
Histamine release after injection of benzodiazepines 
and of etomidate. A problem associated with the 
solvent propylene glycol 
Liberation d'histamine apres injection de benzodiazepines et d'etomidate. 
R61e du solvant propyl6ne-glycol 
A. DOENICKE *, W. LORENZ**, R. HOERNECKE *, A.E. NEBAUER *, M. MAYER * 
• Institut for Anaesthesiologie der LMU MOnchen, Innenstadtkliniken, PettenkoferstraBe 8a, 8000 MOnchen 2, Germany 
• * Theoretische Chirurgie, Philipps-Universitgt, Marburg, Germany 
RI~SUM#: Beaucoup de m6dicaments, urtout quand ils sont inject6s rapidement, peuvent induire une 
lib6ration d'histamine. Une 6tude en ,, cross-over ~ et simple aveugle a 6t6 r6alis6e chez dix volontaires 
sains. Ils ont 6t6 pr6m6diqu6s avec respectivement 10mg - 70 kg t de diaz6pam i.v. et 1 mg - 70 kg ~ de 
lorm6taz6pam i.v., 30 min avant une injection intraveineuse de 0,15 mg- kg ~ d'6tomidate. Le lorm6ta- 
z6pam et l'6tomidate ont produit des augmentations distinctes du niveau d'histamine plasmatique chez 
deux sujets. Les pics maximaux d'histamine aprc3s lorm6taz6pam ont 6t6 respectivement de 2,05 et 
2,7 ng- ml Jet, apr~s 6tomidate, de 1,85 et 3,2 ng- ml -~. Les deux m6dicaments sont solubilis6s dans lc 
propyl~ne-glycol, solvant qui confute une tr~s haute osmolalit6 (6 750 mosm - kg ~ pour le lorm6taz6pam, 
4 900 mosm. kg i pour F6tomidate). Des signes cliniques comme une tachycardie, une hypotension 
art6rielle ou des r6actions allergiques n'ont 6t6 not6s dans aucun cas. Cette lib6ration limit6e d'histamine 
semble cons6cutive au dommage tissulaire et 6rythrocytaire 1i6 ~ I'hyperosmolarit6. 
Dur ing  induct ion  and  maintenance  of  anaesthe-  
sia a var ie ty  of  potent  d rugs  are admin is tered  very  
o f ten  in rap id  sequence .  Each  of  the  drugs  used  
can  potent ia l l y  cause  h i s tamine  re lease.  In the  last 
two decades  many pharmaco log is ts  and  anaesthe-  
s io logists have  invest igated  numerous  hypnot ics ,  
narcot ics  and  musc le  re laxants  in this respect  [1, 
11, 13]. Among the  benzod iazep ines  invest igated  
so far ,  on ly  f lun i t razepam has  been shown to 
re lease  h i s tamine  [1]. 
Ora l  p remedicat ion  wi th  benzod iazep ines ,  
usual ly  1 hour  be fore  the operat ion ,  inc reas ing ly  is 
rep laced  by the  i.v. admin is t ra t ion  of  parentera l  
fo rmulat ions  of  these  drugs  10-20 minutes  pr io r  to 
induct ion  of  anaesthes ia .  In t ravenous  premedica -  
t ion wi th  benzod iazep ines  has  proven  to e f fect ive ly  
reduce  the myoc lon ic  movements  assoc ia ted  wi th  
the use of  e tomidate  [2]. The  a im of  th is  tr ial  is to 
invest igate  whether  i.v. admin is t ra t ion  of  the  two 
benzod iazep ines  d iazepam and lo rmetazepam,  used  
in combinat ion  w i th  e tomidate ,  causes  h i s tamine  
re lease.  
PATIENTS AND METHODS 
After approval by the institutional ethics committee and after 
having obtained their informed consent, 10 healthy volunteers 
(age 20-30 years, weight 50-90 kg) were investigated in this 
single-blind, crossover study. The investigators were not blin- 
ded because, due to its solubility characteristics, it is not 
possible to dilute diazepam to a volume of 5 ml, as needed for 
the administration of lormetazepam. The subjects had a four 
day recovery interval after the first anaesthesia with etomidate 
and premedication with one of the two benzodiazepines. The 
sequence of injection of diazepam and lormetazepam in every 
volunteer was randomized. 
Following amounts of drugs were injected into a distal 
forearm vein : diazepam 10 mg - 70 kg ~ or lormetazepam 
1 rag-70 kg -t, 30 rain prior to etomidate 0.15 mg. kg ~. The 
time table of trial procedure is schematically presented in 
figure 1. 
Blood samples were drawn through a cannula placed in an 
antecubital vein and plasma histamine levels were measured 
according to the fluorometric method described by LORENZ et 
al. [10]. Responders were subjects which presented at least a 
40 % increase in plasma histamine levels from the previous 
baseline value. 
Heart rate was continuously monitored and blood pressure 
was measured in two rain intervals. 
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RESULTS 
Diazepam solved in benzyl-alcohol did not 
release substantial amounts of histamine (slight 
mean increase from 0.35 to 0.61 ng - ml l). 
Plasma levels were well below 1 ng-ml  -~ Mean 
plasma histamine values _+ SD are presented in 
table I. 
Table I. - -  Plasma histamine levels (ng • ml 1) after administra- 
tion of diazepam 10 mg.  70 kg 1 i.v. and Iormetaze.pam 
1 mg • 70 kg -1 i.v., 30 min before etomidate 0.15 mg • kg - ' i . v .  
Before After Before After 
Diazepam Etomidate 
0.35 (0.16) 0.61 (0.17) 0.41 (0.12) 0.54 (0.22) 
Lormetazepam Etomidate 
046 (0.22) 0.98 (0.82) 0.53 (0.33) 0.94 (0.95) 
Mean -+ SD ; n = 10 volunteers ; crossover study with two different i.v. 
premedications (diazepam and Iormetazepam, respectively) 30 min before 
ctomidate injection ; 4 day interval between study sessions. 
Lormetazepam solved in propylene glycol sho- 
wed a distinct histamine release in two subjects 
(fig. 1). According to the elimination kinetics of 
histamine the levels returned to baseline values 
within ten minutes. The subsequent injection of 
etomidate solved in propylene glycol (30 minutes 
later) caused a further liberation of histamine. 
Both volunteers did not show any cardiovascular 
reactions expected with these histamine concentra- 
tions. In both instances diazepam was given on the 
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Fig. 1. - -  Histamine plasma levels in two volunteers after 
injection of diazepam, lormetazepam (6,750 mosm - kg J) and 
etomidate (4,900 mosm - kg-I). 
Histamine plasma levels (ng - ml t) measured in blood samples 
drawn before and 5 min and l0 min after diazepam/lormetaze- 
pare i.v. premedication and I rain after etomidate injection. 
Etomidate was injected 30 min after benzodiazepine adminis- 
tration. There was a four day interval between the two induc- 
tion procedures. 
first trial day and lormetazepam on the second 
day, i.e. four days later. Histamine levels in a 
third volunteer rose from 0.75 to 1.15 ng.  ml -j, 
but did not present a true histamine release accor- 
ding to our definition. 
Myocloni after etomidate application were not 
observed after premedication with lormetazepam, 
but was seen in a mild form in one subject after 
diazepam. 
DISCUSSION 
A previous study on 10 volunteers revealed 
moderate histamine release after i.v. administra- 
tion of flunitrazepam in 5 subjects with a maximal 
histamine level of 1 ng-  ml -l. These were associa- 
ted with cutaneous ymptoms indicating local his- 
tamine liberation [5]. Flunitrazepam was solved in 
829 mg.  ml -~ propylene glycol. In 1978, we found 
elevated histamine levels associated with clinical 
symptoms (erythema) in volunteers receiving the 
muscle relaxants alloferin, pancuronium or suxa- 
methon ium in combination with etomidate [4]. At 
that time we would not find an explanation for 
histamine release after flunitrazepam or etomidate 
in  combination with muscle relaxants. 
In 1973, we had shown that etomidate did not 
release histamine [3]. WAXK1NS (personal commu- 
nication) suggested the possibility of histamine 
release after etomidate, in such small amounts, 
however, that due to its fast elimination from the 
circulation it could not cause haemodynamic 
effects. This was based on the observation of 
subclinical reactions like chemotaxis of leukocytes 
through the surrounding tissue. The production of 
anaphylatoxins following C3-activation reached its 
highest value 30-40 minutes after etomidate admi- 
nistration, whereas methohexital showed this effect 
already after 5 minutes. 
Our own investigations on etomidate solved in 
various solvents may now help to resolve the pro- 
blem on histamine release after etomidate. In 
1973, we had studied histamine release with a 
formulation of etomidate sulphate solved in phos- 
phate buffer. This etomidate preparation had a pH 
of 3.3 and an osmolality of 270 mosm.  kg i [9] 
and did not cause histamine release [3]. Since 1977 
etomidate is formulated in 35 vol % propylene 
glycol_ We now know that its osmolality of 
4,900 mosm-kg  -l is conveyed by the content of 
propylene glycol in the drug preparation [6]. It has 
been shown that replacement of propylene glycol 
with lipid emulsion prevented thrombophlebitis of 
diazepam [7] and significantly reduced the occu- 
fence of pain on injection, thrombophlebitis [2] 
and haemolysis [12] after etomidate injection. 
In the present study, the volunteers received 
etomidate in 35 vol % propylene glycol on two 
occasions and for premedication, once diazepam in 
benzylalcohol, and once lormetazepam in 50 vol % 
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propylene glycol, respectively. Lormetazepam in 
propy lene  g lyco l  has an osmola l i ty  of  
6,750 mosm • kg-l [6]. 
We believe that not only the first injection of 
etomidate after diazepam but also the injection of 
lormetazepam and etomidate four days later, may 
cause osmotical tissue damage. The unphysiologic 
osmolality of these drugs therefore can cause his- 
tamine release from damaged endothelium and/or 
mast cells. The occurrence of pain and thrombo- 
phlebitis reported in previous studies [2, 14] can 
be interpreted as symptoms of irritation of the 
vascular tissue. 
Interestingly the high histamine levels after lor- 
metazepam (2.05 and 2_7 ng- ml -j) and etomidate 
(1.85 and 3.2 ng-ml  -I) observed in two volun- 
teers were not associated with haemodynamic 
reactions or other side effects seen with similar 
histamine concentrations. This may be explained 
by the very short presence of histamine in the 
circulation suggested by WATKINS and the limited 
histamine release from destroyed blood and tissue 
cells, not sustained by cascade mechanism of me- 
diators [13]. 
Independently from this, we advocate the repla- 
cement of solvents that convey an unphysiologic 
osmolality to commercial drug preparations and 
therefore cause vascular and cellular sequelae. Stu- 
dies comparing etomidate solved in propylene gly- 
col and etomidate solved in lipid emulsion with 
medium chain triglycerides have clearly demonstra- 
ted the advantages - -  no pain on injection, no 
thrombophlebitis, no haemolysis - -  of the prepara- 
tion containing the lipid solvent at a physiologic 
osmolality (400 mosm - kg -t ; pH = 7.6 [6]) [2]. 
Since February 1992, etomidate is available in 
Germany in a medium chain triglycerides contai- 
ning lipid emulsion (Etomidat-Lipuro ®). A new 
solvent should also be found for other drugs, 
especially benzodiazepines like lormetazepam, 
lorazepam or flunitrazepam, yet solved in propy- 
lene glycol. 
Promising results have been presented by HABA- 
ZEaL et al. in animal studies with propanidid 
formulated in liposomes. They reported a dramatic 
reduction of mortality due to anaphylactic reac- 
tions in rats from 86 % with propanidid solved in 
cremophor vs 0 % propanidid in the liposome 
formulation [8]. 
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ABSTRACT: Many drugs, especially when given in rapid sequence can cause histamine release. Ten 
healthy volunteers were premedicated with diazepam 10 mg . 70 kg ~ i.v. and lormetazepam 
1 mg . 70 kg ~ i.v., respectively, 30 rain prior to etomidate 0.15 mg-  kg i i.v. in a single-blind, crossover 
study. The benzodiazepine Iormetazepam and the hypnotic etomidate caused distinct increases in hista- 
mine plasma levels in two subjects. Maximal histamine levels after Iormetazepam were 2.05 and 
2.7 ng . ml ~, and after etomidate 1.85 and 3.2 ng-  ml ~, respectively. Both drugs are solved in propy- 
lene glycol, a solvent that conveys very high osmolality (lormetazepam 6 750 mosm.  kg J, etomidate 
4 900 mosm kg t). Clinical symptoms, like tachycardia, hypotension or allergic reactions, associated with 
similar histamine levels were not seen in either case. This limited histamine release appears to be caused 
by osmotic damage of tissue and blood cells. 
